rF-CEA(6D)-TRICOM-infected autologous dendritic cells

rF-CEA(6D)-TRICOM-infected autologous dendritic cells is an investigational cancer vaccine consisting of a patient's own dendritic cells that have been infected ex vivo with a recombinant fowlpox vector. This vector encodes a modified version of the carcinoembryonic antigen (CEA-6D) along with a triad of human costimulatory molecules (TRICOM): B7-1 (CD80), ICAM-1 (CD54), and LFA-3 (CD58). The fowlpox virus is a replication-incompetent avipox virus in human cells. Once the infected dendritic cells are administered back to the patient, they express CEA and the costimulatory molecules, which work synergistically to enhance the activation of CEA-specific T-cell responses. This immunotherapy approach is designed to target and eliminate CEA-expressing tumor cells in various advanced or metastatic malignancies, including colorectal, breast, and lung cancers. The vaccine was developed through a collaboration between Dr. Michael Morse at Duke University, Therion Biologics Corporation, and the National Cancer Institute.

Other names

fowlpox-CEA-TRICOM vaccineautologous dendritic cells infected with fowlpox-CEA-TRICOM